HOUSTON - FibroBiologics, Inc. (NASDAQ:FBLG), a clinical-stage biotech company, announced significant findings from a recent study indicating that dermal fibroblast spheroids may accelerate the healing of chronic wounds in diabetic patients. This research will be presented at the Advanced Wound Care Summit USA in Boston, MA, on April 16-17.
Diabetic foot ulcers (DFUs) affect approximately 33 million people worldwide and present a substantial challenge due to the impaired healing associated with diabetes. The study by FibroBiologics focused on the potential of human dermal fibroblast (HDF) spheroids to promote and hasten the wound healing process.
The research, led by Chief Scientific Officer Hamid Khoja, Ph.D., utilized a diabetic mouse model to assess the therapeutic impact of HDF spheroids on wounds akin to DFUs. The study's key findings showed a 60% reduction in relative wound area within four days post-treatment with HDF spheroids compared to control treatments. It also indicated an upregulation of both pro-inflammatory and anti-inflammatory cytokines, suggesting a favorable wound microenvironment for healing.
Furthermore, the study observed increased levels of vascular endothelial growth factors and receptors, which are indicative of enhanced revascularization and re-epithelialization. Immunohistochemical analysis also revealed markers of fibroblast and endothelial proliferation, active cell proliferation, angiogenesis, and macrophage proliferation in HDF-treated wounds.
Dr. Khoja stated, "These results support the potential of HDF spheroids to expedite the healing process of chronic wounds associated with diabetes." He emphasized the importance of further research and development of fibroblast spheroid-based therapies, especially for patients with DFUs.
The company, which holds over 150 patents and pending applications, is exploring treatments for various chronic diseases, including wound healing, through the use of fibroblast cells and fibroblast-derived materials.
The study's findings are based on a press release statement.
InvestingPro Insights
FibroBiologics, Inc. (NASDAQ:FBLG) has made promising strides in the field of regenerative medicine, particularly with their recent study on dermal fibroblast spheroids. As the company continues its research and development, investors and stakeholders keep a close eye on its financial health and stock performance. Here are some key insights based on real-time data from InvestingPro and InvestingPro Tips:
InvestingPro Data highlights that FibroBiologics has a market capitalization of $363.59 million, illustrating its size and presence within the biotech industry. Despite the potential of their research, the company operates with a negative P/E ratio (last twelve months as of Q4 2023) of -19.08, indicating it is not currently profitable. Additionally, the Price / Book ratio is significantly high at 290.17, suggesting that the market values the company's assets quite optimistically relative to its equity.
InvestingPro Tips reveal that FibroBiologics' stock trades with high price volatility and has experienced a substantial price drop over the last three months, with a -61.55% total return. This could be a point of concern for risk-averse investors. However, the company has seen a strong return over the last month, with a 23.1% price total return, which may interest those looking for short-term gains. It is important to note that FibroBiologics does not pay dividends, which might be a factor for income-focused investors.
For readers interested in a deeper analysis, there are additional InvestingPro Tips available for FibroBiologics at https://www.investing.com/pro/FBLG. To enhance your investment research experience, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.